비교리스트

 카트 문의
시장보고서
상품코드
1508562

부데소니드 흡입기 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Budesonide Inhaler Market (Product Type: Inhalants and Nebulizers, and Dosage Form: Aerosols, Dry Powder, Suspension, and Spray) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 145 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

부데소니드 흡입기 시장 - 조사 범위

TMR의 조사 보고서 "세계의 부데소니드 흡입기 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준 연도 및 2034년을 예측 연도로 간주하여 2018년부터 2034년까지의 세계 부데소니드 흡입기 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 부데소니드 흡입기 시장의 연평균 성장률(CAGR%)을 제시합니다.

이 보고서는 광범위한 1차 연구를 통해 작성되었으며, 분석가들은 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 주요 기업의 제품 자료, 연례 보고서, 보도 자료 및 관련 문서를 참조하여 부데소니드 흡입기 시장을 추론했습니다, 부데소니드 흡입기 시장을 추론했습니다.

시장 현황
2023년 시장 규모 68억 달러
2034년 시장 규모 136억 달러
CAGR 6.6%

이 보고서는 세계 부데소니드 흡입기 시장의 경쟁 환경을 조사했습니다. 세계 부데소니드 흡입기 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등은 세계 부데소니드 흡입기 시장 기업의 속성 중 일부로 이 보고서에서 다루고 있습니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약

제4장 시장 개요

  • 서론
  • 개요
  • 시장 역학
  • 세계 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

  • 파이프라인 분석
  • 주요 제품/브랜드 분석
  • 주요 M&A
  • COVID-19의 산업에 대한 영향

제6장 세계 시장 분석과 예측 : 제품 유형별

  • 서론과 정의
  • 주요 조사 결과와 발전
  • 시장 매출 예측 : 제품 유형별, 2020-2034년
    • 흡입제
    • 네뷸라이저
  • 시장의 매력 : 제품 유형별

제7장 세계 시장 분석과 예측 : 제형별

  • 서론과 정의
  • 주요 조사 결과와 발전
  • 시장 매출 예측 : 제형별, 2020-2034년
    • 에어로졸
    • 건조 분말
    • 서스펜션
    • 스프레이
  • 시장의 매력 : 제형별

제8장 세계 시장 분석과 예측 : 힘별

  • 서론과 정의
  • 주요 조사 결과와 발전
  • 시장 매출 예측 : 힘별, 2020-2034년
    • 0.25mg
    • 0.5mg
  • 시장의 매력 : 힘 별

제9장 세계 시장 분석과 예측 : 적응증별

  • 서론과 정의
  • 주요 조사 결과와 발전
  • 시장 매출 예측 : 적응증별, 2020-2034년
    • 천식
    • 만성 폐쇄성 폐질환(COPD)
  • 시장의 매력 : 적응증별

제10장 세계 시장 분석과 예측 : 유통 채널별

  • 서론과 정의
  • 주요 조사 결과와 발전
  • 시장 매출 예측 : 유통 채널별, 2020-2034년
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장의 매력 : 유통 채널별

제11장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 매출 예측 : 지역별, 2020-2034년
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력 : 지역별

제12장 북미 시장 분석과 예측

제13장 유럽 시장 분석과 예측

제14장 아시아태평양 시장 분석과 예측

제15장 라틴아메리카 시장 분석과 예측

제16장 중동 및 아프리카 시장 분석과 예측

제17장 경쟁 구도

  • 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
  • 시장 점유율 분석 : 기업별(2023년)
  • 기업 개요
    • Pfizer Inc.
    • Cipla Ltd.
    • Lupin Limited
    • Cosmo Pharmaceuticals SA
    • The Takeda Pharmaceutical Company Limited
    • Manus Aktteva Biopharma LLP
    • Abbott Laboratories
    • Aurobindo Pharma Limited
    • Novartis AG
    • Mylan N.V.
LSH 24.07.15

Budesonide Inhaler Market - Scope of Report

TMR's report on the global budesonide inhaler market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global budesonide inhaler market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global budesonide inhaler market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the budesonide inhaler market.

Market Snapshot
Market Value in 2023US$ 6.8 Bn
Market Value in 2034US$ 13.6 Bn
CAGR6.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global budesonide inhaler market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global budesonide inhaler market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global budesonide inhaler market.

The report delves into the competitive landscape of the global budesonide inhaler market. Key players operating in the global budesonide inhaler market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global budesonide inhaler market profiled in this report.

Key Questions Answered in Global budesonide inhaler Market Report:

  • What is the sales/revenue generated by budesonide inhaler across all regions during the forecast period?
  • What are the opportunities in the global budesonide inhaler market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Budesonide Inhaler Market - Research Objectives and Research Approach

The comprehensive report on the global budesonide inhaler market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global budesonide inhaler market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global budesonide inhaler market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Budesonide Inhaler Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Budesonide Inhaler Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Budesonide Inhaler Market Analysis and Forecast, by Product Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2020-2034
    • 6.3.1. Inhalants
    • 6.3.2. Nebulizers
  • 6.4. Market Attractiveness, by Product Type

7. Global Budesonide Inhaler Market Analysis and Forecast, by Dosage Form

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Dosage Form, 2020-2034
    • 7.3.1. Aerosols
    • 7.3.2. Dry Powder
    • 7.3.3. Suspension
    • 7.3.4. Spray
  • 7.4. Market Attractiveness, by Dosage Form

8. Global Budesonide Inhaler Market Analysis and Forecast, By Strength

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, By Strength, 2020-2034
    • 8.3.1. 0.25 mg
    • 8.3.2. 0.5 mg
  • 8.4. Market Attractiveness, By Strength

9. Global Budesonide Inhaler Market Analysis and Forecast, by Indication

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Indication, 2020-2034
    • 9.3.1. Asthma
    • 9.3.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 9.4. Market Attractiveness, by Indication

10. Global Budesonide Inhaler Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction and Definitions
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness, by Distribution Channel

11. Global Budesonide Inhaler Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2020-2034
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness, by Region

12. North America Budesonide Inhaler Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product Type, 2020-2034
    • 12.2.1. Inhalants
    • 12.2.2. Nebulizers
  • 12.3. Market Attractiveness, by Product Type
  • 12.4. Market Value Forecast, by Dosage Form, 2020-2034
    • 12.4.1. Aerosols
    • 12.4.2. Dry Powder
    • 12.4.3. Suspension
    • 12.4.4. Spray
  • 12.5. Market Attractiveness, by Dosage Form
  • 12.6. Market Value Forecast, By Strength, 2020-2034
    • 12.6.1. 0.25 mg
    • 12.6.2. 0.5 mg
  • 12.7. Market Attractiveness, By Strength
  • 12.8. Market Value Forecast, by Indication, 2020-2034
    • 12.8.1. Asthma
    • 12.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 12.9. Market Attractiveness, by Indication
  • 12.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.10.1. Hospital Pharmacies
    • 12.10.2. Retail Pharmacies
    • 12.10.3. Online Pharmacies
  • 12.11. Market Attractiveness, by Distribution Channel
  • 12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.12.1. U.S.
    • 12.12.2. Canada
  • 12.13. Market Attractiveness Analysis
    • 12.13.1. By Product Type
    • 12.13.2. By Dosage Form
    • 12.13.3. By Strength
    • 12.13.4. By Indication
    • 12.13.5. By Distribution Channel
    • 12.13.6. By Country

13. Europe Budesonide Inhaler Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product Type, 2020-2034
    • 13.2.1. Inhalants
    • 13.2.2. Nebulizers
  • 13.3. Market Attractiveness, by Product Type
  • 13.4. Market Value Forecast, by Dosage Form, 2020-2034
    • 13.4.1. Aerosols
    • 13.4.2. Dry Powder
    • 13.4.3. Suspension
    • 13.4.4. Spray
  • 13.5. Market Attractiveness, by Dosage Form
  • 13.6. Market Value Forecast, By Strength, 2020-2034
    • 13.6.1. 0.25 mg
    • 13.6.2. 0.5 mg
  • 13.7. Market Attractiveness, By Strength
  • 13.8. Market Value Forecast, by Indication, 2020-2034
    • 13.8.1. Asthma
    • 13.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 13.9. Market Attractiveness, by Indication
  • 13.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.10.1. Hospital Pharmacies
    • 13.10.2. Retail Pharmacies
    • 13.10.3. Online Pharmacies
  • 13.11. Market Attractiveness, by Distribution Channel
  • 13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.12.1. Germany
    • 13.12.2. U.K.
    • 13.12.3. France
    • 13.12.4. Italy
    • 13.12.5. Spain
    • 13.12.6. Rest of Europe
  • 13.13. Market Attractiveness Analysis
    • 13.13.1. By Product Type
    • 13.13.2. By Dosage Form
    • 13.13.3. By Strength
    • 13.13.4. By Indication
    • 13.13.5. By Distribution Channel
    • 13.13.6. By Country/Sub-region

14. Asia Pacific Budesonide Inhaler Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product Type, 2020-2034
    • 14.2.1. Inhalants
    • 14.2.2. Nebulizers
  • 14.3. Market Attractiveness, by Product Type
  • 14.4. Market Value Forecast, by Dosage Form, 2020-2034
    • 14.4.1. Aerosols
    • 14.4.2. Dry Powder
    • 14.4.3. Suspension
    • 14.4.4. Spray
  • 14.5. Market Attractiveness, by Dosage Form
  • 14.6. Market Value Forecast, By Strength, 2020-2034
    • 14.6.1. 0.25 mg
    • 14.6.2. 0.5 mg
  • 14.7. Market Attractiveness, By Strength
  • 14.8. Market Value Forecast, by Indication, 2020-2034
    • 14.8.1. Asthma
    • 14.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 14.9. Market Attractiveness, by Indication
  • 14.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.10.1. Hospital Pharmacies
    • 14.10.2. Retail Pharmacies
    • 14.10.3. Online Pharmacies
  • 14.11. Market Attractiveness, by Distribution Channel
  • 14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.12.1. China
    • 14.12.2. Japan
    • 14.12.3. India
    • 14.12.4. Australia & New Zealand
    • 14.12.5. Rest of Asia Pacific
  • 14.13. Market Attractiveness Analysis
    • 14.13.1. By Product Type
    • 14.13.2. By Dosage Form
    • 14.13.3. By Strength
    • 14.13.4. By Indication
    • 14.13.5. By Distribution Channel
    • 14.13.6. By Country/Sub-region

15. Latin America Budesonide Inhaler Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Product Type, 2020-2034
    • 15.2.1. Inhalants
    • 15.2.2. Nebulizers
  • 15.3. Market Attractiveness, by Product Type
  • 15.4. Market Value Forecast, by Dosage Form, 2020-2034
    • 15.4.1. Aerosols
    • 15.4.2. Dry Powder
    • 15.4.3. Suspension
    • 15.4.4. Spray
  • 15.5. Market Attractiveness, by Dosage Form
  • 15.6. Market Value Forecast, By Strength, 2020-2034
    • 15.6.1. 0.25 mg
    • 15.6.2. 0.5 mg
  • 15.7. Market Attractiveness, By Strength
  • 15.8. Market Value Forecast, by Indication, 2020-2034
    • 15.8.1. Asthma
    • 15.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 15.9. Market Attractiveness, by Indication
  • 15.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.10.1. Hospital Pharmacies
    • 15.10.2. Retail Pharmacies
    • 15.10.3. Online Pharmacies
  • 15.11. Market Attractiveness, by Distribution Channel
  • 15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.12.1. Brazil
    • 15.12.2. Mexico
    • 15.12.3. Rest of Latin America
  • 15.13. Market Attractiveness Analysis
    • 15.13.1. By Product Type
    • 15.13.2. By Dosage Form
    • 15.13.3. By Strength
    • 15.13.4. By Indication
    • 15.13.5. By Distribution Channel
    • 15.13.6. By Country/Sub-region

16. Middle East & Africa Budesonide Inhaler Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Product Type, 2020-2034
    • 16.2.1. Inhalants
    • 16.2.2. Nebulizers
  • 16.3. Market Attractiveness, by Product Type
  • 16.4. Market Value Forecast, by Dosage Form, 2020-2034
    • 16.4.1. Aerosols
    • 16.4.2. Dry Powder
    • 16.4.3. Suspension
    • 16.4.4. Spray
  • 16.5. Market Attractiveness, by Dosage Form
  • 16.6. Market Value Forecast, By Strength, 2020-2034
    • 16.6.1. 0.25 mg
    • 16.6.2. 0.5 mg
  • 16.7. Market Attractiveness, By Strength
  • 16.8. Market Value Forecast, by Indication, 2020-2034
    • 16.8.1. Asthma
    • 16.8.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 16.9. Market Attractiveness, by Indication
  • 16.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 16.10.1. Hospital Pharmacies
    • 16.10.2. Retail Pharmacies
    • 16.10.3. Online Pharmacies
  • 16.11. Market Attractiveness, by Distribution Channel
  • 16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 16.12.1. GCC Countries
    • 16.12.2. South Africa
    • 16.12.3. Rest of Middle East & Africa
  • 16.13. Market Attractiveness Analysis
    • 16.13.1. By Product Type
    • 16.13.2. By Dosage Form
    • 16.13.3. By Strength
    • 16.13.4. By Indication
    • 16.13.5. By Distribution Channel
    • 16.13.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 17.2. Market Share Analysis, by Company (2023)
  • 17.3. Company Profiles
    • 17.3.1. Pfizer Inc.
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. Cipla Ltd.
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. Lupin Limited
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Cosmo Pharmaceuticals SA
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. The Takeda Pharmaceutical Company Limited
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Manus Aktteva Biopharma LLP
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. Abbott Laboratories
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Aurobindo Pharma Limited
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Novartis AG
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. Mylan N.V.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제